M
MorphoSys
Biotechnology company focused on the research and development of fully human antibodies
At a glance
- Status
- Listed
- Founded
- 1992
- Headquarters
- Planegg, Germany
- Listing
- IPO 2018
- Sector
- Biotech & Life Sciences
- Outcome tier
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Knowledge graph
News
More headlines
Open roles
MorphoSys in the Planegg ecosystem
The MorphoSys office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A4 investors entered at this stage
- GEGenentech
Third Rock Ventures- TGThe Column Group
Venrock
Series B and later4 investors entered at this stage
- MSMax Planck Society
- MIMax Planck Innovation
- MIMax Planck Institute for Biological Intelligence
- MBMax Planck Institute of Biochemistry
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
152 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where MorphoSys was the backer or acquirer, 2010–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
4 deals across MorphoSys's capital deployment.
Where the deals concentrate by sector, stage, and decade.
MorphoSys's portfolio, mapped.
Market sentiment
An AI-synthesised read of the highest-engagement posts about MorphoSys on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MorphoSys on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


